Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice

Atherosclerosis-related CVD causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing lesions. Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with intensive combinations that include alirocuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouwer, Marianne G., Pieterman, Elsbet J., Worms, Nicole, Keijzer, Nanda, Jukema, J. Wouter, Gromada, Jesper, Gusarova, Viktoria, Princen, Hans M. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Biochemistry and Molecular Biology 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053846/
https://www.ncbi.nlm.nih.gov/pubmed/31843957
http://dx.doi.org/10.1194/jlr.RA119000419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053846/
https://www.ncbi.nlm.nih.gov/pubmed/31843957
http://dx.doi.org/10.1194/jlr.RA119000419

Ejemplares similares